Amarin Corporation plc (NASDAQ:AMRN) Files An 8-K Results of Operations and Financial Condition

Item2.02.

On May3, 2017, Amarin Corporation plc issued a press release
announcing its financial results for the three months ended
March31, 2017 (the Press Release). A copy of the Press Release is
furnished herewith as Exhibit 99.1.

The information in this report furnished to Item 2.02 shall
not be deemed filed for purposes of Section18 of the Securities
Exchange Act of 1934, as amended (the Exchange Act), or otherwise
subject to the liabilities of that section. It may only be
incorporated by reference in another filing under the Exchange
Act or the Securities Act of 1933, as amended, if such subsequent
filing specifically references the information furnished to Item
2.02 of this report.

(d) Exhibits

* * *

About Amarin Corporation plc (NASDAQ:AMRN)

Amarin Corporation plc is a biopharmaceutical company with operations in lipid science focused on the commercialization and development of therapeutics for cardiovascular health. The Company operates through the development and commercialization of Vascepa segment. The Company’s lead product, Vascepa (icosapent ethyl) capsule, is approved by the United States Food and Drug Administration (FDA) for use as an adjunct to diet to reduce triglyceride levels in adult patients with severe hypertriglyceridemia. This indication for Vascepa, known as the MARINE indication, is based primarily on the results from the MARINE study of Vascepa in this approved patient population. The Company sells Vascepa principally to wholesalers, as well as selected regional wholesalers and specialty pharmacy providers, or collectively, its distributors, which in turn resell Vascepa to retail pharmacies for resale to patients and healthcare providers.

Amarin Corporation plc (NASDAQ:AMRN) Recent Trading Information

Amarin Corporation plc (NASDAQ:AMRN) closed its last trading session down -0.01 at 3.17 with 1,524,589 shares trading hands.